INmune Bio Inc
NASDAQ:INMB
INmune Bio Inc
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2019-02-04. The firm is focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Its drug candidates include INKmune, INB03, and XPro1595 (XPro). The company has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor alpha (TNF), a driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is being developed for Alzheimer's and treatment-resistant depression (XPro) and cancer (INB03). The Natural Killer (NK) Cell Priming Platform includes INKmune for priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic malignancies, solid tumors, and chronic inflammation.
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2019-02-04. The firm is focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Its drug candidates include INKmune, INB03, and XPro1595 (XPro). The company has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor alpha (TNF), a driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is being developed for Alzheimer's and treatment-resistant depression (XPro) and cancer (INB03). The Natural Killer (NK) Cell Priming Platform includes INKmune for priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic malignancies, solid tumors, and chronic inflammation.
Financial Performance: Net loss narrowed to $6.5 million for Q3 2025 from $12.1 million last year, driven by lower R&D expenses.
Cash Runway: The company has $27.7 million in cash, which is expected to fund operations into Q4 2026.
CORDStrom Progress: CORDStrom is moving toward regulatory filings for RDEB, with a U.K. marketing application expected in mid-2026 and a U.S. BLA to follow.
XPro Alzheimer's Program: Positive Phase II results in highly inflamed patients; regulatory engagement for an accelerated pathway is ongoing, with key FDA interactions set for early 2026.
INKmune Update: Phase II trial in prostate cancer met its primary endpoint and two of three secondary endpoints; further data analysis is ongoing with plans for a randomized Phase II trial.
Pipeline Strategy: Management emphasized the strength of its diversified pipeline, with three different drug platforms advancing in parallel.
Upcoming Milestones: Major clinical and regulatory milestones for CORDStrom and XPro are expected throughout 2026.
